Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8895499rdf:typepubmed:Citationlld:pubmed
pubmed-article:8895499lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C0057223lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C0010762lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C1332830lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C1264638lld:lifeskim
pubmed-article:8895499lifeskim:mentionsumls-concept:C0243102lld:lifeskim
pubmed-article:8895499pubmed:issue10lld:pubmed
pubmed-article:8895499pubmed:dateCreated1996-12-5lld:pubmed
pubmed-article:8895499pubmed:abstractTextThe possible association between lung cancer and the CYP2D6*9 mutant allele, which reduces the catalytic activity of cytochrome P450 CYP2D6, was examined by PCR-SSCP using peripheral blood DNA from 249 cases of lung cancer and 265 controls, with detailed data on smoking. The CYP2D6*9 mutant allele was present in 4.9% of controls and 6% of cases. Adjusted for age, hospital and smoking, the odds ratio (OR) of lung cancer associated with the presence of the CYP2D6*9 mutant allele was 1.2 [95% confidence interval (CI) 0.5-2.9]. According to histological type, adenocarcinoma and small cell carcinoma were not associated with the presence of the CYP2D6*9 mutant allele and a non-significant higher occurrence of the mutant allele was observed for squamous cell carcinoma (OR 1.74, 95% CI 0.6-4.8). Moreover, no associations were observed upon stratification by number of pack-years of cigarette smoking. These results do not confirm an earlier report that this CYP2D6*9 mutant allele may be an additional risk factor for the development of lung cancer.lld:pubmed
pubmed-article:8895499pubmed:languageenglld:pubmed
pubmed-article:8895499pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8895499pubmed:citationSubsetIMlld:pubmed
pubmed-article:8895499pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8895499pubmed:statusMEDLINElld:pubmed
pubmed-article:8895499pubmed:monthOctlld:pubmed
pubmed-article:8895499pubmed:issn0143-3334lld:pubmed
pubmed-article:8895499pubmed:authorpubmed-author:LegrandMMlld:pubmed
pubmed-article:8895499pubmed:authorpubmed-author:MarekSSlld:pubmed
pubmed-article:8895499pubmed:authorpubmed-author:Lo-GuidiceJ...lld:pubmed
pubmed-article:8895499pubmed:authorpubmed-author:BrolyFFlld:pubmed
pubmed-article:8895499pubmed:authorpubmed-author:StuckerIIlld:pubmed
pubmed-article:8895499pubmed:authorpubmed-author:SabbaghNNlld:pubmed
pubmed-article:8895499pubmed:issnTypePrintlld:pubmed
pubmed-article:8895499pubmed:volume17lld:pubmed
pubmed-article:8895499pubmed:ownerNLMlld:pubmed
pubmed-article:8895499pubmed:authorsCompleteYlld:pubmed
pubmed-article:8895499pubmed:pagination2267-9lld:pubmed
pubmed-article:8895499pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:meshHeadingpubmed-meshheading:8895499-...lld:pubmed
pubmed-article:8895499pubmed:year1996lld:pubmed
pubmed-article:8895499pubmed:articleTitleInfluence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility.lld:pubmed
pubmed-article:8895499pubmed:affiliationLaboratoire de Biochimie et Biologie Moleculaire de l'Hopital Calmette, Centre Hospitalier Regional et Universitaire de Lille, France.lld:pubmed
pubmed-article:8895499pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8895499pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8895499lld:pubmed